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Stage 2 Supportive care









































Stage 3 Supportive care



































Stage 4 Supportive care





























































Figure 1. RF Event Rates in the Supportive 
Care and Eculizumab Treatment Phases
CI,	confidence	interval;	RF,	renal	failure
aPer	90	days	of	eligibility.



















Table 1. Frequency of progression to a  







































	 	 •	 	HR for	progression	to	ESRD	for	
patients	on	eculizumab	compared	
to	supportive	care:	0.034,	P<0.001)	
(Figure 2A).
	 –	 	No	patients	who	initiated	eculizumab	in	
CKD	Stage	2	or	3	progressed	to	ESRD	
during	3	years	of	treatment	(Figures 2B 
and C).
	 –	 	For	patients	initiating	eculizumab	in	CKD	
Stage	4,	there	was	a	92%	reduction	in	
progression	to	ESRD	(HR	for	progression	
to	ESRD	compared	with	supportive	care:	
0.088,	P=0.0054)	(Figure 2D).
P329
P	values	were	determined	from	log-rank	tests	of	equality	of	survival	distributions.
CI,	confidence	interval;	CKD,	chronic	kidney	disease;	ESRD,	end-stage	renal	disease;	HR,	hazard	ratio.
